FrancophonIA/ELRC3.0 huggingface dataset:
English: Uncommon: Oral candidiasis, nasopharyngitis, cellulitis, herpes simplex, viral infection, pneumonia, catheter-related infection, fungal infection, herpes zoster, injection site infection, sepsis2, neutropenic sepsis2
Croatian: Manje često: oralna kandidijaza, nazofaringits, celulitis, herpes simplex, virusna infekcija, pneumonija, infekcija povezana s kateterom, gljivična infekcija, herpes zoster, infekcija na mjestu injekcije, sepsa2, neutropenijska sepsa2
English: Women of childbearing potential should use effective contraception during treatment and up to 1 month after receiving treatment with Abraxane.
Croatian: Žene reproduktivne dobi moraju koristiti učinkovitu kontracepciju tijekom liječenja i do mjesec dana nakon završetka liječenja lijekom Abraxane.
English: Table 1: Dose level reductions for patients with pancreatic adenocarcinoma Dose Level
Croatian: Tablica 1: Smanjivanje razine doza u bolesnika s adenokarcinomom pankreasa Razina doze
English: The study compared Abraxane in combination with carboplatin versus solvent-based paclitaxel in combination with carboplatin as first-line treatment in patients with advanced non-small cell lung cancer.
Croatian: U ispitivanju se uspoređivao Abraxane u kombinaciji s karboplatinom i paklitaksel na bazi otapala u kombinaciji s karboplatinom kao prva linija liječenja bolesnika s uznapredovalim karcinomom nemalih stanica pluća.
English: Abraxane should only be administered under the supervision of a qualified oncologist in units specialised in the administration of cytotoxic agents.
Croatian: Abraxane treba primjenjivati samo pod nadzorom kvalificiranog onkologa na odjelima koji su specijalizirani za primjenu citotoksičnih lijekova.
English: For febrile neutropenia, withhold Abraxane and gemcitabine until fever resolves and ANC ≥ 1500 cells/mm3, then resume treatment at reduced dose levels (see section 4.2).
Croatian: U slučaju febrilne neutropenije, treba obustaviti Abraxane i gemcitabin dok se vrućica ne povuče i ne dosegne ABN ≥ 1500 stanica/mm3, a potom nastaviti liječenje pri smanjenoj razini doza (vidjeti dio 4.2).
English: If Abraxane contacts mucous membranes, the membranes should be flushed thoroughly with water.
Croatian: Ako Abraxane dođe u dodir sa sluznicama, potrebno ih je temeljito isprati vodom.
English: No patients treated with Abraxane and carboplatin experienced Grade 4 peripheral neuropathy.
Croatian: Nijedan bolesnik liječen Abraxaneom s karboplatinom nije imao perifernu neuropatiju 4. stupnja.
English: Abraxane contains sodium
Croatian: Abraxane sadrži natrij.
English: Common: Increased lacrimation, blurred vision, dry eye, keratoconjunctivitis sicca, madarosis
Croatian: Često: pojačano suzenje, zamućeni vid, suho oko, keratokonjunktivitis sicca, madaroza
English: Women of childbearing potential should have a pregnancy test prior to starting treatment with Abraxane.
Croatian: Žene u reproduktivnoj dobi trebaju se testirati na trudnoću prije početka liječenja lijekom Abraxane.
English: For combination use of Abraxane and carboplatin, if Grade 3 or higher peripheral neuropathy develops, treatment should be withheld until improvement to Grade 0 or 1 followed by a dose reduction for all subsequent courses of Abraxane and carboplatin (see section 4.2).
Croatian: Ako se kod primjene Abraxanea u kombinaciji s karboplatinom razvije periferna neuropatija 3. ili višeg stupnja, liječenje se mora obustaviti do poboljšanja na stupanj 0 ili 1, iza čega slijedi smanjenje doze u svim sljedećim ciklusima primjene Abraxanea i karboplatina (vidjeti dio 4.2).
English: Patients who have baseline neutrophil counts <1500 cells/mm3.
Croatian: Bolesnici s početnim brojem neutrofila < 1500 stanica/mm3.
English: • Nausea, diarrhoea, constipation, sore mouth, loss of appetite
Croatian: • mučnina, proljev, zatvor, rane u ustima, gubitak apetita
English: Common: Dehydration, decreased appetite, hypokalaemia Uncommon: Hypophosphataemia, fluid retention, hypoalbuminaemia, polydipsia, hyperglycaemia, hypocalcaemia, hypoglycaemia, hyponatraemia
Croatian: Često: dehidracija, smanjeni apetit, hipokalijemija Manje često: hipofosfatemija, retencija tekućine, hipoalbuminemija, polidipsija, hiperglikemija, hipokalcijemija, hipoglikemija, hiponatrijemija
English: This multi-centre trial was conducted in patients with metastatic breast cancer, who were treated every 3 weeks with single-agent paclitaxel, either as solvent-based paclitaxel 175 mg/m2 given as a 3-hour infusion with premedication to prevent hypersensitivity (N = 225), or as Abraxane 260 mg/m2 given as a
Croatian: Ovo multicentrično ispitivanje provedeno je na bolesnicima s metastatskim karcinomom dojke liječenim svaka tri tjedna paklitakselom kao jedinim lijekom, bilo paklitakselom baziranom na otapalu u dozi od 175 mg/m2 u obliku trosatne infuzije s premedikacijom za sprječavanje preosjetljivosti (N = 225) ili lijekom Abraxane u dozi od 260 mg/m2 u obliku 30-minutne infuzije bez premedikacije
English: Non-small cell lung cancer (Abraxane administered in combination with carboplatin)
Croatian: Karcinom nemalih stanica pluća (Abraxane primijenjen u kombinaciji s karboplatinom)
English: Two hundred and twenty nine patients treated with Abraxane in the randomized, controlled clinical trial were evaluated for safety.
Croatian: U randomiziranom, kontroliranom kliničkom ispitivanju 229 bolesnika liječenih lijekom Abraxane podvrgnuto je procjeni sigurnosti.
English: In a study in patients with advanced solid tumours, the pharmacokinetic characteristics of paclitaxel following Abraxane administered intravenously at 260 mg/m2 over 30 minutes were compared with those following 175 mg/m2 of the solvent-based paclitaxel injection administered over 3 hours.
Croatian: U ispitivanju na bolesnicima s uznapredovalim solidnim tumorima uspoređivane su farmakokinetičke značajke paklitaksela nakon intravenske primjene lijeka Abraxane u dozi od 260 mg/m2 tijekom 30 minuta s onima nakon primjene injekcije paklitaksela baziranog na otapalu u dozi od 175 mg/m2
English: Withhold doses until improves to ≤ Grade 1; resume at next lower dose levela a. See Table 1 for dose level reductions
Croatian: Obustaviti doze do poboljšanja na ≤ 1. stupnja; nastaviti sa sljedećom nižom razinom dozaa aZa smanjenje razina doza vidjeti tablicu 1.
English: The other ingredient is human albumin (containing sodium, sodium caprylate and N-acetyl DL tryptophanate).
Croatian: Drugi sastojak je ljudski albumin (koji sadrži natrij, natrijev kaprilat i N-acetil DL triptofanat).
English: Progression-free Survivala (independent review)
Croatian: Preživljenje bez progresije bolestia (neovisna procjena)
English: The recommended dose of carboplatin is AUC = 6 mg•min/mL on Day 1 only of each 21-day cycle, beginning immediately after the end of Abraxane administration.
Croatian: Preporučena doza karboplatina je AUC = 6 mg•min/ml, odmah nakon završene primjene lijeka Abraxane, samo 1. dana svakog 21-dnevnog ciklusa.
English: Sepsis was reported at a rate of 5% in patients with or without neutropenia who received Abraxane in combination with gemcitabine during the conduct of a trial in pancreatic adenocarcinoma.
Croatian: Sepsa u stopi od 5% zabilježena je u bolesnika s neutropenijom ili bez nje koji su primali Abraxane u kombinaciji s gemcitabinom u ispitivanju adenokarcinoma pankreasa.
English: The pharmacokinetics of total paclitaxel following 30- and 180-minute infusions of Abraxane at dose levels of 80 to 375 mg/m2 were determined in clinical studies.
Croatian: Farmakokinetika ukupnog paklitaksela određena je u kliničkim ispitivanjima nakon infuzija lijeka Abraxane od 30 i 180 minuta u rasponima doze od 80 do 375 mg/m2.
English: Survival (months) Progression-free Survival Death or progression, n (%) Median Progression-free Survival, months (95% CI) HRA+G/G (95% CI)a P-valueb
Croatian: 75. percentil sveukupnog preživljenja (mjeseci) Preživljenje bez progresije bolesti Smrt ili progresija, n (%) Medijan preživljenja bez progresije, mjeseci (95% CI) HRA+G/G (95% CI)a P-vrijednostb
English: Reconstituted suspension: It can be stored refrigerated at 2°C to 8°C for up to 24 hours in either the vial or an infusion bag, protected from light.
Croatian: Rekonstituirana suspenzija: može se čuvati u hladnjaku na temperaturi od 2°C do 8°C do 24 sata u bočici ili vrećici za infuziju, zaštićena od svjetlosti.
English: Sepsis was reported at a rate of 5% in patients with or without neutropenia who received Abraxane in combination with gemcitabine.
Croatian: Sepsa u stopi od 5% zabilježena je u bolesnika s neutropenijom ili bez nje koji su primali Abraxane u kombinaciji s gemcitabinom.
English: • Reduction in the number of platelets in the blood
Croatian: • smanjenje broja trombocita u krvi
English: Abraxane should not be administered until neutrophil counts recover to >1500 cells/mm3.
Croatian: Abraxane se ne smije primjenjivati sve dok broj neutrofila ne poraste na > 1500 stanica/mm3.
English: Common: Insomnia, depression, anxiety Uncommon: Restlessness
Croatian: Često: nesanica, depresija, anksioznost Manje često: anksioznost
English: No patients treated with Abraxane in combination with gemcitabine had Grade 4 peripheral neuropathy.
Croatian: Nijedan bolesnik liječen Abraxaneom s gemcitabinom nije imao perifernu neuropatiju 4. stupnja.
English: 100 ml vial (type 1 glass) with a stopper (butyl rubber), with an overseal (aluminium), containing 250 mg of paclitaxel formulated as albumin bound nanoparticles.
Croatian: Bočica od 100 ml (staklo tipa 1) s čepom (od butilne gume), s prstenom (aluminij), koja sadrži 250 mg paklitaksela u obliku nanočestica vezanih na albumin.
English: CI = confidence interval; HRA/T = hazard ratio of Abraxane/carboplatin to solvent-based paclitaxel/carboplatin; pA/pT = response rate ratio of Abraxane/carboplatin to solvent-based paclitaxel/carboplatin.
Croatian: CI = interval pouzdanosti, HRA/T = omjer hazarda za Abraxane/karboplatin naspram paklitaksel baziran na otapalu/karboplatin; pA/pT = omjer stope odgovora za Abraxane/karboplatin naspram paklitaksel baziran na otapalu/karboplatin a P-vrijednost se temelji na hi-kvadrat testu
English: Table 9 lists adverse reactions associated with the administration of Abraxane in combination with carboplatin.
Croatian: Tablica 9 navodi nuspojave povezane s primjenom lijeka Abraxane u kombinaciji s karboplatinom.
English: Very common: Arthralgia, myalgia Common: Back pain, pain in extremity, musculoskeletal pain
Croatian: Vrlo često: artralgija, mijalgija Često: bol u leđima, bol u udovima, mišićno-koštani bol
English: Stability of the reconstituted suspension in the infusion bag Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C-8°C followed by 4 hours at 25°C, protected from light.
Croatian: Stabilnost rekonstituirane suspenzije u vrećici za infuziju Kemijska i fizikalna stabilnost suspenzije u primjeni dokazana je tijekom 24 sata na temperaturi od 2°C do 8°C nakon kojih je uslijedilo 4 sata na 25°C, uz zaštitu od svjetlosti.
English: Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C-8°C in the original carton, protected from light.
Croatian: Kemijska i fizikalna stabilnost suspenzije u primjeni dokazana je tijekom 24 sata na temperaturi od 2°C do 8°C u originalnom pakiranju, uz zaštitu od svjetlosti.
English: If patients experience nausea, vomiting and diarrhoea following the administration of Abraxane, they may be treated with commonly used anti-emetics and constipating agents.
Croatian: Ako nakon primjene lijeka Abraxane bolesnici osjećaju mučninu, povraćaju i imaju proljev, može ih se liječiti uobičajenim antiemeticima i lijekovima protiv proljeva.
English: Table 12: Overall response rate in randomized non-small cell lung cancer trial (intent-to-treat population)
Croatian: Tablica 12: Ukupna stopa odgovora u randomiziranom kliničkom ispitivanju bolesnika s karcinomom nemalih stanica pluća (populacija s namjerom liječenja)
English: Common: Nail disorder, pruritus, dry skin, erythema, nail pigmentation/discolouration, skin hyperpigmentation, onycholysis, nail changes
Croatian: Često: poremećaji noktiju, svrbež, suha koža, eritem, pigmentacija noktiju/promjena boje, hiperpigmentacija kože, oniholiza, promjene na noktima
English: pA+G/pG (95% CI)
Croatian: HRA+G/G (95% CI)a P-vrijednostb
English: How to store Abraxane
Croatian: Kako primjenjivati Abraxane
English: Scleroderma of the skin has been reported.
Croatian: Zabilježena je skleroderma.
English: The PL should be updated accordingly.
Croatian: Uputu o lijeku potrebno je ažurirati u skladu s tim.
English: Of the 421 patients with pancreatic adenocarcinoma in the randomized study who received Abraxane in combination with gemcitabine, 41% were 65 years and older and 10% were 75 years and older.
Croatian: U randomiziranom ispitivanju, od 421 bolesnika s adenokarcinomom pankreasa koji su primali Abraxane u kombinaciji s gemcitabinom, 41% bolesnika bilo je u dobi od 65 i više godina, a 10% u dobi od 75 i više godina.
English: 20.9 [15.7, 25.9] (n = 131)
Croatian: > 1. linije terapije 20,9 [15,7; 25,9] (n = 131)
English: Very common: Neutropenia, anaemia, leukopenia, thrombocytopenia, lymphopenia, bone marrow suppression Common: Febrile neutropenia
Croatian: Vrlo često: neutropenija, anemija, leukopenija, trombocitopenija, limfopenija, supresija koštane srži Često: febrilna neutropenija
English: Day 8 ≥ 500 but < 1000 OR ≥ 50,000 but < 75,000
Croatian: 8. dan ≥ 500 ali < 1000 ILI ≥ 50000 ali < 75000
English: After reconstitution, each ml of suspension contains 5 mg of paclitaxel formulated as albumin bound nanoparticles.
Croatian: Nakon rekonstitucije, svaki ml suspenzije sadrži 5 mg paklitaksela u obliku nanočestica vezanih na albumin.
English: Not known side effects (frequency cannot be estimated from the available data):
Croatian: Nepoznato (učestalost se ne može se procijeniti iz dostupnih podataka): • zadebljanje kože (skleroderma).
English: Very common: Diarrhoea, vomiting, nausea, constipation
Croatian: Vrlo često: proljev, povraćanje, mučnina, konstipacija
English: Reconstituted Abraxane suspension is administered intravenously using an infusion set incorporating a 15 µm filter.
Croatian: Rekonstituirana suspenzija lijeka Abraxane primjenjuje se intravenski, s pomoću kompleta za infuziju opremljenog filtrom od 15 µm.
English: In
Croatian: I
English: 1On Day 1 of the 21-day cycle reduce the dose of Abraxane and carboplatin simultaneously.
Croatian: 1Dozu lijeka Abraxane i karboplatina smanjite istodobno 1. dana 21-dnevnog ciklusa.
English: toxic epidermal necrolysis)
Croatian: Nehematološka toksičnost
English: Frequent monitoring of blood cell counts should be performed during Abraxane therapy.
Croatian: Tijekom liječenja lijekom Abraxane često treba kontrolirati broj krvnih stanica.
English: Unopened vials: Keep the vial in the outer carton in order to protect from light.
Croatian: Neotvorene bočice: Bočicu čuvati u vanjskom pakiranju radi zaštite od svjetlosti.
English: Pneumonitis has been reported at a rate of 4% with the use of Abraxane in combination with gemcitabine.
Croatian: Pneumonitis je zabilježen u stopi od 4% bolesnika kada se Abraxane primjenjivao u kombinaciji s gemcitabinom.
English: Uncommon: Contusion
Croatian: Manje često: kontuzija
English: The recommended dose of Abraxane is 100 mg/m2 administered as an intravenous infusion over 30 minutes on Days 1, 8 and 15 of each 21-day cycle.
Croatian: Preporučena doza lijeka Abraxane je 100 mg/m2 primijenjena kao intravenska infuzija tijekom 30 minuta 1., 8. i 15. dana svakog 21-dnevnog ciklusa.
English: The second trial utilised a dose of 300 mg/m2 as a 30 minute infusion in 63
Croatian: U drugom je ispitivanju korištena doza od 300 mg/m2
English: Very common: Pain in extremity, arthralgia, myalgia Common: Muscular weakness, bone pain
Croatian: Vrlo često: bol u udovima, artralgija, mijalgija Često: mišićna slabost, bol u kostima
English: Patients should not be retreated with subsequent cycles of Abraxane until neutrophils recover to >1500 cells/mm3 and platelets recover to >100,000 cells/mm3 (see section
Croatian: Bolesnike se ne smije nastaviti liječiti narednim ciklusima lijeka Abraxane sve dok broj neutrofila ne poraste na > 1500 stanica/mm3, a broj trombocita na > 100 000 stanica/mm3 (vidjeti dio 4.2).
English: Uncommon: Drug hypersensitivity, hypersensitivity
Croatian: Manje često: preosjetljivost na lijek, preosjetljivost
English: The usual dose is for breast cancer is 260 mg/m2 of body surface area given over a 30 minute period.
Croatian: Uobičajena doza za rak dojke iznosi 260 mg/m2 tjelesne površine i daje se tijekom 30 minuta.
English: Abraxane(125 mg/m2)/
Croatian: Abraxane(125 mg/m2)/ gemcitabin
English: CNS metastases
Croatian: Metastaze u SŽS-u
English: The very rare side effects may affect up to 1 in 10,000 people:
Croatian: Vrlo rijetke nuspojave mogu se pojaviti u do 1 na 10 000 osoba:
English: Uncommon: Nail bed tenderness, urticaria, skin pain, photosensitivity reaction, pigmentation disorder, pruritic rash, skin disorder, hyperhidrosis, onychomadesis, erythematous rash, generalised rash, dermatitis, night sweats, maculo-papular rash, vitiligo, hypotrichosis, nail discomfort, generalized pruritus, macular rash, papular rash, skin lesion, swollen face
Croatian: Manje često: osjetljivost ležišta nokta, urtikarija, bolna koža, fotosenzitivna reakcija, poremećaj pigmentacije, pruritički osip, poremećaj kože, hiperhidroza, onihomadeza, eritematozni osip, generalizirani osip, dermatitis, noćno znojenje, makulopapularni osip, vitiligo, hipotrihoza, nelagoda u noktima, generalizirani svrbež, makularni osip, papularni osip, lezije na koži, natečeno lice
English: Common: Pneumonia, bronchitis, upper respiratory tract infection, urinary tract infection
Croatian: Često: pneumonija, bronhitis, infekcija gornjeg dijela dišnog sustava, infekcija mokraćnog sustava
English: Common: Decreased weight, increased alanine aminotransferase, increased aspartate aminotransferase, decreased haematocrit, decreased red blood cell count, increased body temperature, increased gamma-glutamyltransferase, increased blood alkaline phosphatase
Croatian: Često: smanjena težina, povišena razina alanin aminotransferaze, povišena razina aspartat aminotransferaze, smanjeni hematokrit, smanjeni broj eritrocita, povišena tjelesna temperatura, povišena razina gama glutamiltransferaze, povišena razina alkalne fosfataze u krvi
English: • Difficulty walking, swelling
Croatian: • otežano hodanje, otečenost
English: MARKETING AUTHORISATION NUMBER(S) EU/1/07/428/001
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/07/428/001
English: • Acute kidney failure
Croatian: • akutno zatajenje bubrega
English: Table 7: Adverse reactions reported with Abraxane in combination with gemcitabine (N =421) Infections and infestations
Croatian: Tablica 7: Nuspojave zabilježene uz Abraxane primijenjen u kombinaciji s gemcitabinom (N = 421)
English: Table 5: Dose reductions for non-haematologic toxicities in patients with non-small cell lung cancer Non-haematologic Toxicity
Croatian: Tablica 5: Smanjivanje doze zbog nehematoloških toksičnosti u bolesnika s karcinomom nemalih stanica pluća
English: Human albumin solution (containing sodium, sodium caprylate and N-acetyl DL tryptophanate).
Croatian: Otopina ljudskog albumina (koja sadrži natrij, natrijev kaprilat i N-acetil DL triptofanat).
English: MARKETING AUTHORISATION NUMBER(S) EU/1/07/428/002
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/07/428/002
English: Hepatobiliary disorders Uncommon: Hepatomegaly
Croatian: Poremećaji jetre i žuči Manje često: hepatomegalija
English: Occurrence Dose of Abraxane (mg/m2)1
Croatian: Doza lijeka Abraxane (mg/m2)1
English: Cycle Day
Croatian: ROK VALJANOSTI
English: Lung Cancer
Croatian: Rak pluća
English: Table 4: Dose reductions for haematologic toxicities in patients with non-small cell lung cancer Haematologic Toxicity
Croatian: Tablica 4: Smanjivanje doze zbog hematoloških toksičnosti u bolesnika s karcinomom nemalih stanica pluća
English: Common: Infection, urinary tract infection, folliculitis, upper respiratory tract infection, candidiasis, sinusitis
Croatian: Često: infekcija, infekcija mokraćnog sustava, folikulitis, infekcija gornjeg dijela dišnog sustava, kandidijaza, sinusitis
English: Reduce doses 1 dose level from Day 1 doses
Croatian: smanjenje razine doza 1. dana za 1 razinu
English: NAME OF THE MEDICINAL PRODUCT Abraxane 5 mg/ml powder for suspension for infusion.
Croatian: Abraxane 5 mg/ml prašak za suspenziju za infuziju.
English: The concurrent recommended dose of gemcitabine is 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of Abraxane administration on Days 1, 8 and 15 of each 28-day cycle.
Croatian: Istodobna preporučena doza gemcitabina iznosi 1000 mg/m2 primijenjeno intravenski tijekom 30 minuta, odmah nakon završene primjene lijeka Abraxane 1., 8. i 15. dana svakog 28-dnevnog ciklusa.
English: Uncommon: Productive cough, exertional dyspnoea, sinus congestion, decreased breath sounds, pleural effusion, allergic rhinitis, hoarseness, nasal congestion, nasal dryness, wheezing, pulmonary emboli, pulmonary thromboembolism
Croatian: Manje često: produktivni kašalj, dispneja pri naporu, kongestija sinusa, manje čujno disanje, pleuralna efuzija, alergijski rinitis, promuklost, nazalna kongestija, suhoća nosa, piskanje, plućni embolusi, plućna tromboembolija
English: Return to Day 1 dose levels and follow with WBC Growth Factors
Croatian: Povratak na razinu doza 1. dana i zatim primjena čimbenika rasta bijelih krvnih stanica ILI
English: Administer reconstituted Abraxane suspension intravenously using an infusion set incorporating a 15 µm filter.
Croatian: Rekonstituiranu suspenziju lijeka Abraxane primijenite intravenski, s pomoću kompleta za infuziju opremljenog filtrom od 15 µm.
English: Abraxane Dose (mg/m2)
Croatian: Doza lijeka Abraxane (mg/m2)
English: Very common: Fatigue, asthenia, oedema peripheral Common: Pyrexia, chest pain
Croatian: Vrlo često: umor, astenija, periferni edem Često: pireksija, bol u prsima
English: The recommended dose of Abraxane in combination with gemcitabine is 125 mg/m2 administered intravenously over 30 minutes on Days 1, 8 and 15 of each 28-day cycle.
Croatian: Preporučena doza lijeka Abraxane u kombinaciji s gemcitabinom iznosi 125 mg/m2, a primjenjuje se intravenski tijekom 30 minuta 1., 8. i 15. dana svakog 28-dnevnog ciklusa.
English: Common: Lacrimation increased Uncommon: Cystoid macular oedema
Croatian: Često: pojačano suzenje Manje često: cistoidni makularni edem
English: Very common: Dehydration, decreased appetite, hypokalaemia
Croatian: Poremećaji metabolizma i prehrane Vrlo često: dehidracija, smanjeni apetit, hipokalijemija Psihijatrijski poremećaji
English: It is not known if paclitaxel is excreted in human milk.
Croatian: Nije poznato izlučuje li se paklitaksel u majčino mlijeko u ljudi.
English: Very common: Rash, alopecia Common: Pruritus, nail disorder Uncommon: Skin exfoliation, dermatitis allergic, urticaria
Croatian: Često: pruritus, poremećaj noktiju Manje često: eksfolijacija kože, alergijski dermatitis, urtikarija
English: Very common: Dyspnoea, epistaxis, cough Common: Pneumonitis2, nasal congestion Uncommon: Dry throat, nasal dryness
Croatian: Vrlo često:dispneja, epistaksa, kašalj Često: pneumonitis2, nazalna kongestija Manje često: suho grlo, suhoća nosa
English: Each vial contains 100 mg or 250 mg of paclitaxel formulated as albumin bound nanoparticles.
Croatian: Svaka bočica sadrži 100 mg ili 250 mg paklitaksela u obliku nanočestica vezanih na albumin.
English: Very common: Alopecia, rash Common: Pruritus, dry skin, nail disorder, flushing
Croatian: Vrlo često: alopecija, osip Često: pruritus, suha koža, poremećaji noktiju, crvenilo uz osjećaj vrućine
English: Common: Flushing, hot flushes, hypertension, lymphoedema Uncommon: Hypotension, peripheral coldness, orthostatic hypotension Rare: Thrombosis
Croatian: Često: crvenilo uz osjećaj vrućine, navale vrućine, hipertenzija, limfedem Manje često: hipotenzija, periferna hladnoća, ortostatska hipotenzija
English: Common: Sepsis, pneumonia, oral candidiasis
Croatian: Infekcije i infestacije Često: sepsa, pneumonija, oralna kandidijaza